Prudential Financial Inc Vera Therapeutics, Inc. Transaction History

Prudential Financial Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$18.86 - $32.0 $406,244 - $689,280	-21,540 Reduced 25.77%	62,037 $1.46 Million
Q1 2025 May 13, 2025	BUY	$24.02 - $43.22 $12,010 - $21,610	500 Added 0.6%	83,577 $2.01 Million
Q4 2024 Feb 11, 2025	BUY	$38.64 - $49.75 $806,803 - $1.04 Million	20,880 Added 33.57%	83,077 $3.51 Million
Q3 2024 Nov 13, 2024	BUY	$34.09 - $46.71 $446,067 - $611,200	13,085 Added 26.64%	62,197 $2.75 Million
Q2 2024 Aug 13, 2024	BUY	$33.72 - $48.82 $1.66 Million - $2.4 Million	49,112 New	49,112 $1.78 Million

194

65.9M

128K

172K

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $766M
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.